114 related articles for article (PubMed ID: 35979540)
1. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.
Gbolahan O; Hashemi-Sadraei N; Yash S; Williams G; Ramachandran R; Kim YI; Paluri R; Outlaw D; El-Rayes B; Nabell L
Cancer Med; 2023 Feb; 12(3):3488-3498. PubMed ID: 35979540
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.
Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
[TBL] [Abstract][Full Text] [Related]
5. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
[TBL] [Abstract][Full Text] [Related]
6. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
Cushman TR; Jones B; Akhavan D; Rusthoven CG; Verma V; Salgia R; Sedrak M; Massarelli E; Welsh JW; Amini A
Clin Lung Cancer; 2021 Jan; 22(1):e84-e97. PubMed ID: 33039348
[TBL] [Abstract][Full Text] [Related]
8. No impact of time to treatment initiation for head and neck cancer in a tertiary university center in 2003, 2008 and 2013.
Kouka M; Engelhardt M; Wittig A; Schultze-Mosgau S; Ernst T; Guntinas-Lichius O
Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4549-4560. PubMed ID: 35488907
[TBL] [Abstract][Full Text] [Related]
9. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.
Murphy CT; Galloway TJ; Handorf EA; Egleston BL; Wang LS; Mehra R; Flieder DB; Ridge JA
J Clin Oncol; 2016 Jan; 34(2):169-78. PubMed ID: 26628469
[TBL] [Abstract][Full Text] [Related]
10. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
11. Palliative resection of the primary tumour improves survival in incurable metastatic colorectal cancer.
Inci K; Nilsson B; Lindskog S; Giglio D
ANZ J Surg; 2023 Nov; 93(11):2680-2685. PubMed ID: 37489624
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis.
Ramadan M; Alfayea T; Alsofyani A; Alyabsi M; Alhusseini N; Algarni AS
Cancer Treat Res Commun; 2022; 33():100632. PubMed ID: 36088745
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
14. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
[No Abstract] [Full Text] [Related]
16. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
[TBL] [Abstract][Full Text] [Related]
17. Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Meng L; Thapa R; Delgado MG; Gomez MF; Ji R; Knepper TC; Hubbard JM; Wang X; Permuth JB; Kim RD; Laber DA; Xie H
JAMA Netw Open; 2023 Jun; 6(6):e2320035. PubMed ID: 37358854
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
[Next] [New Search]